Exyte acquires TTP Group to accelerate growth of biopharma and life sciences business
TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry
TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
The grant is designated for the research and development of Pyronaridine
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Subscribe To Our Newsletter & Stay Updated